Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension

Rheumatology

Volumn 49, Issue 11, 2010, Pages 2147-2153

  Valerio, Christopher J ^a   Handler, Clive E ^a   Kabunga, Peter ^a   Smith, Colette J ^b   Denton, Christopher P ^c   Coghlan, John G ^a  

^a The National Pulmonary Hypertension Unit   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Bosentan; Connective tissue disease; Drugs; Endothelin receptors; Endothelin 1; Pulmonary circulation; Pulmonary hypertension; Sitaxentan; Systemic sclerosis

Indexed keywords

BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; HEMOGLOBIN; PLACEBO; SILDENAFIL; SITAXSENTAN; UNIPROST; WARFARIN;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DATA BASE; DRUG FATALITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART CATHETER; HEART CATHETERIZATION; HEMODYNAMICS; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFORMATION PROCESSING; LOG RANK TEST; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PATIENT ASSESSMENT; PHYSICIAN; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; CONNECTIVE TISSUE DISEASES; FEMALE; HUMANS; HYPERTENSION, PULMONARY; ISOXAZOLES; MALE; MIDDLE AGED; STATISTICS AS TOPIC; SULFONAMIDES; THIOPHENES; TREATMENT OUTCOME;

EID: 78649361810     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq241     Document Type: Article

References (23)

1. Simmoneau G, Robbins IM, Beghetti M et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54(Suppl. S):S43-54.
2. Condliffe R, Kiely DG, Peacock AJ et al. Connective tissue disease associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179:151-7.
3. Galiè N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004;61: 227-37.
4. Galiè N, Hoeper MM, Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009;30:2493-537.
5. Dingemanse J, van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 2004;43:1089-115.
6. Wu C, Chan MF, Stavros F et al. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem 1997;40:1690-7.
7. Channick RN, Simmoneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23.
8. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896-903.
9. Barst RJ, Langleben D, Frost A et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441-7.
10. Barst RJ, Langleben D, Badesch D et al. Treatment of pulmonary arterial hypertension with the selective Bosentan and sitaxentan in CTD-PAH endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47:2049-56.
11. Benza RL, Barst RJ, Galiè N et al. Sitaxsentan for the treatment of pulmonary arterial hypertension. A 1-year, prospective, open-label observation of outcome and survival. Chest 2008;134:775-82.
12. Highland KB, Strange C, Girgis RE, Black C. Comparison of sitaxentan and bosentan in pulmonary arterial hypertension associated with connective tissue disease [abstract]. Ann Rheum Dis 2006;65(Suppl. II):393.
13. Langleben D, Cacoub P. A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade. Eur J Clin Invest 2009;39(Suppl. 2): 27-31.
14. Opitz CF, Ewert R, Kirch W, Pittrow D. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J 2008; 29:1936-48.
15. Steiner MK, Preston IR. Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension. Vasc Health Risk Manag 2008;4:943-52.
16. MacIntyre IM, Dhaun N, Goddard J, Webb DJ. Sitaxsentan sodium for pulmonary hypertension. Drugs Today 2008; 44:585-600.
17. Price LC, Howard LS. Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy. Am J Cardiovasc Drugs 2008;8:171-85.
18. Badesch DB, Champion HC, Sanchez MAG et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(Suppl. S):S55-66.
19. Denton CP, Humbert M, Rubin LJ, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006;65:1336-40.
20. Seibold JR, Langleben D, Badesch DB, Naeije R, Galiè N, Barst RJ. Sitaxentan, a selective endothelin-A receptor antagonist, improves exercise capacity in PAH associated with CTD [abstract]. Ann Rheum Dis 2006;65(Suppl. II): 522.
21. Davie N, Haleen SJ, Upton PD et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002;165:398-405.
22. Burgess G, Hoogkamer H, Collings L, Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 2008;64:43-50.
23. Coyne TC, Garces PC, Kramer W. No clinical interaction between sitaxsentan and sildenaEl [abstract]. Ann Rheum Dis 2005;64:275.